This Phase I/II study evaluated the safety, tolerance, pharmacokinetics and antiviral activity of the anti-HIV antisense oligonucleotide GEM 91 administered by continuous intravenous infusion for up to 14 days. We enrolled and administered study drug to 9 HIV-infected subjects as part of this protocol. The drug infusion produced transient elevation of hepatic transaminases in a few subjects, transient mild thrombocytopenia in some, and sterile superficial thrombophlebitis in one subject. No significant reduction in HIV plasma RNA was seen with this study treatment.
Showing the most recent 10 out of 1014 publications